BackRegeneron Pharmaceuticals Overview
Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals Target Price

See Regeneron Pharmaceuticals's analyst price targets ($820) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$796.02

Average Target Price

$815.602.5% upside

15 analysts in the last 4 months

High: $1030 | Low: $730

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-10HSBCRajesh Kumar$92015.6% upsideOpen
2026-08-17Leerink PartnersDavid Risinger$8243.5% upsideOpen
2026-08-14BernsteinJeffrey Walch$7565% downsideOpen
2026-08-03Guggenheim$1,03029.4% upsideOpen
2026-07-31Morgan Stanley$7584.8% downsideOpen
2026-07-31Cantor FitzgeraldCarter Gould$7950.1% downsideOpen
2026-07-31Robert W. Baird$7614.4% downsideOpen
2026-07-31Wells Fargo$7505.8% downsideOpen
2026-07-31RBC Capital$7377.4% downsideOpen
2026-07-21GuggenheimYatin Suneja$1,00025.6% upsideOpen
2026-07-09Piper SandlerBiren Amin$8547.3% upsideOpen
2026-07-08Morgan StanleyTerence Flynn$7308.3% downsideOpen
2026-07-07Truist Financial$7693.4% downsideOpen
2026-07-06Cantor Fitzgerald$7505.8% downsideOpen
2026-07-06HSBC$8000.5% upsideOpen
2026-05-19Canaccord GenuityJohn Newman$8759.9% upsideOpen
2026-05-18Wolfe ResearchAlexandria Hammond$8608% upsideOpen
2026-05-18Leerink PartnersMarket Perform$64119.5% downsideOpen
2026-05-18Truist Financial$7782.3% downsideOpen
2026-05-18BMO Capital$7308.3% downsideOpen
2026-05-18Evercore ISI$8253.6% upsideOpen
2026-05-18Piper Sandler$8557.4% upsideOpen
2026-05-18RBC Capital$70711.2% downsideOpen
2026-05-01GuggenheimYatin Suneja$99525% upsideOpen
2026-04-30Morgan StanleyTerence Flynn$7881% downsideOpen
2026-04-30Truist Financial$7960% upsideOpen
2026-04-30Barclays$91715.2% upsideOpen
2026-04-22Raymond JamesChris Raymond$91014.3% upsideOpen
2026-04-10Morgan Stanley$7960% upsideOpen
2026-04-08Bernstein$92115.7% upsideOpen
2026-03-09Truist FinancialGreg Renza$8182.8% upsideOpen
2026-03-06BarclaysEliana Merle$92316% upsideOpen
2026-03-02RBC CapitalBrian Abrahams$7653.9% downsideOpen
2026-02-09Guggenheim$97522.5% upsideOpen
2026-02-02Cantor FitzgeraldCarter Gould$8000.5% upsideOpen
2026-02-02Tudor PickeringWilliam Pickering$92516.2% upsideOpen
2026-02-02Oppenheimer$8658.7% upsideOpen
2026-02-02Robert W. BairdBrian Skorney$7426.8% downsideOpen
2026-02-01Morgan StanleyTerence Flynn$7693.4% downsideOpen
2026-01-30Raymond James$8709.3% upsideOpen
2026-01-27Tudor PickeringWilliam Pickering$91615.1% upsideOpen
2026-01-27Bernstein$91615.1% upsideOpen
2026-01-27RBC CapitalBrian Abrahams$7456.4% downsideOpen
2026-01-22Evercore ISI$8759.9% upsideOpen
2026-01-08Goldman Sachs$91414.8% upsideOpen
2025-12-17Leerink PartnersAndrew Berens$8739.7% upsideOpen
2025-12-12Morgan StanleyTerence Flynn$7683.5% downsideOpen
2025-12-10HSBC$98523.7% upsideOpen
2025-12-04Canaccord Genuity$1,05732.8% upsideOpen
2025-12-04BMO CapitalEvan Seigerman$8506.8% upsideOpen

Regeneron Pharmaceuticals (REGN) FAQ

As of the most recent data, REGN shows a target price of $820. Scroll down for historical charts and peer comparison views.

If Regeneron Pharmaceuticals moved to the average analyst target of $820, shares would be roughly 2.5% higher than $796.02. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Regeneron Pharmaceuticals's earnings trajectory.

Besides this target price page, Stockcircle has Regeneron Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $820) with ownership activity and broader fundamentals.

Regeneron Pharmaceuticals's target price is $820; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.